In Silico - About the company
In Silico is a public company based in Boston (United States), founded in 2014 by Alex Zhavoronkov and Stephanie Williams. It operates as an AI-enabled bioinformatics platform for drug discovery and biomarker development. In Silico has raised $510M in funding from investors like Qiming Venture Partners, Warburg Pincus and WuXi AppTec. The company has 213 active competitors, including 71 funded and 13 that have exited. Its top competitors include companies like Schrodinger, Recursion Pharmaceuticals and Valo Health.
Sectors and market segments that In Silico operate in
In Silico serves in the HealthTech, Life Sciences, High Tech, Native AI market segments.The primary business model of In Silico are:Company Details
AI-enabled bioinformatics platform for drug discovery and biomarker development. The company provides solutions and services such as custom drug discovery engines, biomarker discovery, and aging research tools to academia, pharmaceutical, and cosmetics companies. Also, it has developed a product PHARMA.AI which includes modules for drug discovery such as PandaOmics, Chemistry42, and InClinico.
- Website
- insilico.com
- Email ID
- *****@insilico.com
Key Metrics
Founded Year
2014
Location
Boston, United States
Stage
Public
Total Funding
$510M in 12 rounds
Latest Funding Round
Investors
Ranked
7th among 213 active competitors
Annual Revenue
$1 - $1M as on Jul 18, 2017
Employee Count
287 as on Sep 30, 2026
Similar Companies
Exit Details
Public
Legal entities associated with In Silico
In Silico is associated with 1 legal entity given below:
Legal Entity Name | Date of Incorporation | Revenue | Latest Employee Count | Documents |
|---|---|---|---|---|
Insilico Medicine, Inc. CIN: 1698493 , United States, Active | $1 - $1M (As on Jul 18, 2017) | - | - |
In Silico's IPO details
In Silico got listed on Dec 30, 2025.
Click here to take a look at In Silico's IPO in detail
Sign up to download In Silico's company profile
In Silico's funding and investors
In Silico has raised a total funding of $510M over 12 rounds. Its first funding round was on Apr 01, 2014. Its latest funding round was a Series E round on Jan 07, 2025 for $110M. 2 investors participated in its latest round. In Silico has 37 institutional investors and 1 angel investor.
Here is the list of recent funding rounds of In Silico:
Filter this list
Filter this listDate of Funding | Funding Amount | Round Name | Post-Money Valuation | Revenue Multiple | Lead Investors | Other Investors |
|---|---|---|---|---|---|---|
Jan 07, 2025 | $110M | Series E | $1B | - | - | |
Aug 11, 2022 | $35M | Series D | - | - | - | |
Jun 07, 2022 | $60M | Series D | $1B | - |
Access funding benchmarks and valuations. Sign up today!View details of In Silico's funding rounds and investors
In Silico's founders and board of directors
Founder? Claim ProfileThe founders of In Silico are Alex Zhavoronkov and Stephanie Williams. Alex Zhavoronkov and Feng Ren are the CEOs of In Silico.
Here are the details of In Silico's key team members:
- Alex Zhavoronkov: Co-Founder & Co-CEO of In Silico. They are also an angel investor in 1 startup.Contact Info: 1 email address
- Stephanie Williams: Co-Founder of In Silico. Contact Info: 1 email address
- Feng Ren: Co-CEO of In Silico. Contact Info: 1 email address
View details of In Silico's Founder profiles and Board Members
In Silico's employee count trend
In Silico has 287 employees as of Sep 26. Here is In Silico's employee count trend over the years:
Uncover In Silico's growth story! Sign up today!
Access Tracxn on any website
Install Tracxn ExtensionOur Google Chrome extension lets you view company details while browsing their websites
In Silico's Competitors and alternates
Top competitors of In Silico include Schrodinger, Recursion Pharmaceuticals and Valo Health. Here is the list of Top 10 competitors of In Silico, ranked by Tracxn score:
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!
Rank | Company Details | Short Description | Total Funding | Investors | Tracxn Score |
|---|---|---|---|---|---|
1st |  Schrodinger 1990, New York City (United States), Acquired | Provider of a web-based simulation and modelling tool | $162M | 74/100 | |
2nd | Recursion Pharmaceuticals 2013, New York (United States), Public | AI-enabled drug discovery and development platform for novel therapeutics | $452M | 72/100 | |
3rd |  Valo Health 2019, Boston (United States), Series B | AI-powered platform for drug discovery and development | $450M | 67/100 | |
4th |  XtalPi 2014, Cambridge (United States), Public | AI-based drug research and development company | $785M | 67/100 | |
5th |  Isomorphic Labs 2021, London (United Kingdom), Series B | Digital platform focused on revolutionizing drug discovery using AI | $2.7B | 64/100 | |
6th |  Xaira 2023, San Francisco (United States), Series D | AI-enabled platform for drug discovery and development | $1B | 63/100 | |
7th |  In Silico 2014, Boston (United States), Public | AI-enabled bioinformatics platform for drug discovery and biomarker development | $510M | 64/100 | |
8th |  Tandem AI 2021, New York (United States), Series A | AI-based drug discovery tool for researchers | $82M | 62/100 | |
9th | Causaly 2018, London (United Kingdom), Series B | Provider of an AI platform for life sciences and biomedical research | $93M | 62/100 | |
10th | Provider of an AI and quantum physics to discover therapeutic molecules | $101M | 62/100 |
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!Looking for more details on In Silico's competitors? Click here to see the top ones
In Silico's Investments and acquisitions
In Silico has made no investments or acquisitions yet.
Reports related to In Silico
Here is the latest report on In Silico's sector:
News related to In Silico
Filter this listMedia has covered In Silico for a total of 47 events in the last 1 year, 20 of them have been about company updates and 14 about partnerships.
•
Insilico Medicine Releases AI Longevity Discovery Toolkit to Researchers WorldwidePR Newswire•Sep 17, 2026•In Silico
•
Insilico Medicine Doses First Patient in World's First Generative AI-Driven Phase III Trial for IPFPR Newswire•Sep 10, 2026•In Silico
•
Insilico Medicine Introduces Biological Age into Virtual Cell ResearchPR Newswire•Aug 14, 2026•In Silico
•
Insilico CEO Promises More Deals After Billions in TransactionsBioSpace•Aug 11, 2026•In Silico, Hong Kong Investment Corporation Limited, Shanghai Pudong Development Bank
•
Insilico Medicine Discovers New Mechanism and Drug Candidate for Chronic Pain TreatmentDonanimhaber•Jul 23, 2026•In Silico
•
BlueNexus Secures A$2.0M Seed Funding Led by M31 CapitalThe SaaS News•Jul 16, 2026•M31 Capital, Antler, In Silico, Eastend Ventures
•
Insilico Medicine and Bora Pharmaceuticals Announce Strategic Alliance for AI-Driven Drug DiscoveryPR Newswire•Jul 15, 2026•Bora Pharmaceuticals, In Silico
•
Insilico Medicine and CMS Expand AI-Powered Drug Discovery Collaboration for CNS DiseasesPR Newswire•Jul 13, 2026•In Silico
•
Zhangjiang Pharma Valley fuels biotech momentumChina Daily•Jul 10, 2026•MicroPort Orthopedics, In Silico
•
Insilico Medicine Releases Positive Profit Alert for the First Half of 2026PR Newswire•Jul 09, 2026•In Silico
Get curated news about company updates, funding rounds, M&A deals and others. Sign up today!Are you a Founder ?
FAQs about In Silico
Explore our recently published companies
- Datamap - San Martin based, 2026 founded, Unfunded company
- Aveneo Home - Germany based, 2026 founded, Unfunded company
- Clickfone - Germany based, 2026 founded, Unfunded company
- Aion Systems AI - 2026 founded, Unfunded company
- Arvum Partners - 2026 founded, Unfunded company
- Anticipai - Netherlands based, 2026 founded, Unfunded company
